公开(公告)号：US10786492B2

公开(公告)日：2020-09-29

申请号：US16211139

申请日：2018-12-05

Applicant: Novartis AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Pascal Furet ,  Thomas Knoepfel ,  Catherine Leblanc ,  Robert Mah

IPC: C07D401/12 ,  C07D401/14 ,  A61K31/444 ,  A61K31/4427 ,  C07D213/75 ,  C07D405/14 ,  A61P35/00 ,  A61K31/497

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US10130629B2

公开(公告)日：2018-11-20

申请号：US15561209

申请日：2016-03-23

Applicant: Novartis AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Jorge Garcia Fortanet ,  Pascal Furet ,  Diana Graus Porta ,  Nafeeza Hafeez ,  Bo Han ,  Thomas Knoepfel ,  Matthew J. LaMarche ,  Catherine Leblanc ,  Lv Liao ,  Robert Mah ,  Dale Porter ,  Can Wang ,  Markus Wartmann ,  Jing Xiong ,  Xianglin Zhao

IPC: A61K31/496 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377

Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

公开(公告)号：US09040559B2

公开(公告)日：2015-05-26

申请号：US14450692

申请日：2014-08-04

Applicant: Novartis AG

Inventor： Bernard Cuenoud ,  Ian Bruce ,  Robin Alec Fairhurst ,  David Beattie

IPC: A61K31/395 ,  A61K31/4709 ,  C07C215/80 ,  C07C233/43 ,  C07C311/08 ,  C07D215/227 ,  C07D215/26 ,  C07D405/12 ,  A61K45/06

CPC classification number: A61K31/4709 ,  A61K45/06 ,  C07C215/80 ,  C07C233/43 ,  C07C311/08 ,  C07C2602/08 ,  C07D215/227 ,  C07D215/26 ,  C07D405/12

Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Abstract translation: 其中Ar为式Y的化合物为碳或氮，R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，X，n，p， q和r如说明书中所定义，它们的制备及其作为药物的用途，特别是用于治疗阻塞性或炎症性气道疾病。